ShEEP request for a Helios CyTOF MS

摘要 贝德福德VA医院申请资金购买Helios CyTOF飞行时间 原子质谱仪（MS），由Fluidigm制造。目前，我院MS 实验室配备了Q Exactive混合Orbitrap MS，Quantiva三重四极杆MS， 和QSTAR MS/MS系统。新的Helios CyTOF MS将联合收割机细胞计数器， 电感耦合等离子体、飞行时间MS集成到一台仪器中。完全不同 来自现有的MS仪器。随着Helios CyTOF MS的加入，我们将扩大核心 贝德福德VA医院研发项目的生物标志物检测能力。 该仪器将在支持的多学科临床研究中发挥重要作用 通过VA，为我们提供了一个无与伦比的能力，表型和功能概况细胞 从正常状态到疾病状态。Helios CyTOF MS将用于多个VA资助的 Xia、Stein和Hanlon博士（主要用户）指导的研究，沿着其他主要研究人员 贝德福德VA医院的研究者（未成年用户）（Moo、Morin、威尔斯、谢梅诺夫博士）， 波士顿VA卫生系统（司机和拉斯穆森博士）和哥伦比亚VA医院（顾博士）。 Helios CyTOF MS将用于分析各种各样的生物样品进行研究 与中枢神经系统紊乱有关具体而言，它将用于表征诱导的 多能干细胞（iPSC），并了解和促进重编程过程， 外周血单核细胞（PBMC）至iPSC。将预测对治疗的反应 (Aim 1）。Helios CyTOF将用于帮助确定受试者的外周生物标志物 患有慢性创伤性脑病或路易体痴呆症， 基于神经病理学和近红外（NIR）光谱的分析（Aim 2）。单细胞 Helios CyTOF获得的蛋白质组学将与血液中的代谢组学和脂质组学一起进行分析 来自阿尔茨海默病（AD）患者的样品（Aim 3）。最后，多种生物标志物研究 由VA和NIH支持，将通过Helios的单细胞蛋白质组学分析得到证实 CyTOF（Aim 4）。

Abstract The Bedford VA hospital requests for fund to acquire the Helios CyTOF time-of-flight atomic Mass Spectrometer (MS), manufactured by Fluidigm. Currently, our hospital MS laboratory is equipped with a Q Exactive hybrid Orbitrap MS, a Quantiva Triple Quadrupole MS, and a QSTAR MS/MS system. The new Helios CyTOF MS will combine cell cytometer, inductively coupled plasma, time-of-flight MS into a single instrument. It is completely different from existing MS instruments. With the addition of Helios CyTOF MS, we will expand core biomarker detection capability at the Bedford VA Hospital Research and Development program. This instrument will play an important role in multi-disciplinary clinical studies that are supported by VA, providing us with an unparalleled ability to phenotypically and functionally profile cells from normal and diseased states. The Helios CyTOF MS will be used for multiple VA funded studies directed by Drs. Xia, Stein and Hanlon (major users), along with other principal investigators (minor users) at the Bedford VA Hospital (Drs. Moo, Morin, Wells, Semenov), Boston VA Health System (Drs. Driver and Rasmusson), and Columbia VA Hospital (Dr. Gu). The Helios CyTOF MS will be used to analyze a large variety of biological samples for studies related to central nervous system disorders. Specifically, it will be used to characterize induced pluripotent stem cells (iPSC) and to understand and facilitate the reprogramming process from peripheral blood mononuclear cells (PBMC) to iPSC. Response to therapeutics will be predicted (Aim 1). The Helios CyTOF will be used to help establish peripheral biomarkers from subjects with chronic traumatic encephalopathy or Lewy Body Dementia and correlate to neuropathological and Near Infrared (NIR) spectra based analysis (Aim 2). Single-cell proteomics obtained by Helios CyTOF will be profiled with metabolomics and lipidomics in blood samples from Alzheimer’s disease (AD) patients (Aim 3). Finally, multiple biomarker studies supported by VA and NIH will be corroborated by single-cell proteomic profiling with Helios CyTOF (Aim 4).